Sugi Predict

Sugi Predict / Compounds / SCHEMBL391606

SCHEMBL391606

SCHEMBL391606

COC(=O)c1ccc(=O)n(C)c1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.49
▸ GAA P10253 5/20 0.42
▸ KDM4E B2RXH2 5/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ GLA P06280 3/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ ATM Q13315 2/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ CFTR P13569 2/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ PDK2 Q15119 1/20 0.41
▸ PDK4 Q16654 1/20 0.41
▸ CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4142698 0.80 KDM4E (0.47) ABL1GAAKDM4EALDH1A1GLA
SCHEMBL13560139 0.79 KMT2A (0.38) GAAKDM4EALDH1A1HSD17B10MAPT
SCHEMBL12130341 0.79 SMN1; SMN2 (0.39) KDM4EALDH1A1CASP1BRD4CA12
SCHEMBL15803863 0.78 KMT2A (0.39) GAAKDM4EALDH1A1GLAHSD17B10
SCHEMBL25308830 0.77 CA1 (0.43) ABL1GAAKDM4EALDH1A1GLA
SCHEMBL31032995 0.75 GABRA1 (0.47) ABL1GAAKDM4EALDH1A1GLA
SCHEMBL15050905 0.74 ABL1 (0.47) ABL1GAAKDM4EALDH1A1GLA
SCHEMBL14269810 0.73 ABL1 (0.46) ABL1GAAKDM4EALDH1A1GLA
SCHEMBL388866 0.72 ABL1 (0.42) ABL1GAAKDM4EALDH1A1GLA
SCHEMBL523584 0.72 ABL1 (0.57) ABL1GAAKDM4EALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117561255-A 3, 4-dihydro-2, 7-naphthyridine-1, 6 (2H, 7H) -dione compounds as MEK inhibitors 辉瑞公司 2024-02-13 — — CN disclosed
CN-117062818-A Novel SOS1 inhibitor and preparation method and application thereof 南京再明医药有限公司 2023-11-14 — — CN disclosed
CN-115043842-A Amino-substituted bicyclic inhibitor and preparation method and application thereof 苏州泽璟生物制药股份有限公司 2022-09-13 — — CN disclosed
WO-2022184116-A1 NEW SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏先声药业有限公司 2022-09-09 — — WO disclosed
CN-111704611-A Aryl spiro SHP2 inhibitor compound, preparation method and application 上海凌达生物医药有限公司 2020-09-25 — — CN disclosed
CN-106478496-A Dihydropyridine sulfonamide and dihydropyridine sulphamide as mek inhibitor 阿迪生物科学公司 2017-03-08 — — CN disclosed
EP-2411366-B1 DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS ARDEA BIOSCIENCES INC (US) 2015-05-20 — — EP disclosed
EP-2364973-B1 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2014-07-09 — — EP disclosed
US-8673919-B2 Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors ARDEA BIOSCIENCES, INC. (US) 2014-03-18 — — US disclosed
US-8673919-B2 Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors ARDEA BIOSCIENCES, INC. (US) 2014-03-18 — — US disclosed
EP-1967516-A1 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases Array Biopharma, Inc. (US) 2008-09-10 — — EP disclosed
EP-1922307-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2008-05-21 — — EP disclosed
US-20070112038-A1 Heterocyclic inhibitors of MEK and methods of use thereof ARRAY BIOPHARMA INC. 2007-05-17 — — US disclosed
WO-2007044084-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-04-19 — — WO disclosed
WO-2007044084-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-04-19 — — WO disclosed
EP-1682138-A4 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2007-01-24 — — EP disclosed
EP-1682138-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2006-07-26 — — EP disclosed
US-20050256123-A1 Heterocyclic inhibitors of MEK and methods of use thereof ARRAY BIOPHARMA INC. 2005-11-17 — — US disclosed
US-20050250782-A1 Heterocyclic inhibitors of MEK and methods of use thereof ARRAY BIOPHARMA INC. 2005-11-10 — — US disclosed
WO-2005051301-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112038-A1 Heterocyclic inhibitors of MEK and methods of use thereof NRAS, BRAF, MAPK9 ABL1 147/4885GAA 2737/4885KDM4E 665/4885
US-20050250782-A1 Heterocyclic inhibitors of MEK and methods of use thereof NRAS, BRAF, MAPK9 ABL1 149/4885GAA 2818/4885KDM4E 889/4885
US-20050256123-A1 Heterocyclic inhibitors of MEK and methods of use thereof NRAS, BRAF, MAPK9 ABL1 146/4885GAA 2856/4885KDM4E 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.